maccura(SZ:300463) Xin Lang Zheng Quan·2025-09-26 01:26Core Viewpoint - The financial performance of Maike Biological is declining, with significant decreases in both revenue and net profit for the first half of 2025, indicating potential challenges ahead for the company [2]. Group 1: Financial Performance - As of June 30, 2025, Maike Biological reported a revenue of 1.075 billion yuan, a year-on-year decrease of 15.94% [2]. - The net profit attributable to shareholders for the same period was 34.04 million yuan, reflecting a substantial year-on-year decline of 83.12% [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.278 billion yuan, with 370 million yuan distributed over the past three years [3]. Group 2: Market Activity - On September 25, 2023, Maike Biological's stock price fell by 0.68%, with a trading volume of 59.31 million yuan [1]. - The financing buy-in amount for the same day was 10.33 million yuan, while the financing repayment was 10.75 million yuan, resulting in a net financing outflow of 416,000 yuan [1]. - The total balance of margin trading for Maike Biological as of September 25, 2023, was 325 million yuan, with the financing balance accounting for 4.60% of the circulating market value [1]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Maike Biological was 35,000, a slight decrease of 0.18% from the previous period [2]. - The average number of circulating shares per shareholder increased by 0.25% to 14,031 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 5.1207 million shares, a decrease of 8.7749 million shares compared to the previous period [3].